224 related articles for article (PubMed ID: 27151564)
1. Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery.
Fu Q; Hargrove D; Lu X
Nanomedicine; 2016 Oct; 12(7):1951-1959. PubMed ID: 27151564
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes.
Jia L; Shen J; Li Z; Zhang D; Zhang Q; Liu G; Zheng D; Tian X
Int J Pharm; 2013 Mar; 445(1-2):12-9. PubMed ID: 23384728
[TBL] [Abstract][Full Text] [Related]
3. Overcoming multiple gastrointestinal barriers by bilayer modified hollow mesoporous silica nanocarriers.
Wang Y; Zhao Y; Cui Y; Zhao Q; Zhang Q; Musetti S; Kinghorn KA; Wang S
Acta Biomater; 2018 Jan; 65():405-416. PubMed ID: 29037897
[TBL] [Abstract][Full Text] [Related]
4. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
[TBL] [Abstract][Full Text] [Related]
5. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
[TBL] [Abstract][Full Text] [Related]
6. Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel.
Tsai M; Lu Z; Wang J; Yeh TK; Wientjes MG; Au JL
Pharm Res; 2007 Sep; 24(9):1691-701. PubMed ID: 17447121
[TBL] [Abstract][Full Text] [Related]
7. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
8. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer.
Slapak EJ; El Mandili M; Ten Brink MS; Kros A; Bijlsma MF; Spek CA
Cancer Lett; 2024 May; 590():216845. PubMed ID: 38589004
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance.
Jia L; Li Z; Shen J; Zheng D; Tian X; Guo H; Chang P
Int J Pharm; 2015 Jul; 489(1-2):318-30. PubMed ID: 25956050
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer.
Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
[TBL] [Abstract][Full Text] [Related]
11. Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB.
Zhu J; Zhang Y; Chen X; Zhang Y; Zhang K; Zheng H; Wei Y; Zheng H; Zhu J; Wu F; Piao JG; Zhu Z; Li F
Biochem Biophys Res Commun; 2021 Jan; 534():902-907. PubMed ID: 33162028
[TBL] [Abstract][Full Text] [Related]
12. Effect of pH-responsive alginate/chitosan multilayers coating on delivery efficiency, cellular uptake and biodistribution of mesoporous silica nanoparticles based nanocarriers.
Feng W; Nie W; He C; Zhou X; Chen L; Qiu K; Wang W; Yin Z
ACS Appl Mater Interfaces; 2014 Jun; 6(11):8447-60. PubMed ID: 24745551
[TBL] [Abstract][Full Text] [Related]
13. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals.
Lu J; Liong M; Li Z; Zink JI; Tamanoi F
Small; 2010 Aug; 6(16):1794-805. PubMed ID: 20623530
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
15. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
16. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
[TBL] [Abstract][Full Text] [Related]
17. PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden.
Gao J; Fan K; Jin Y; Zhao L; Wang Q; Tang Y; Xu H; Liu Z; Wang S; Lin J; Lin D
Eur J Pharm Sci; 2019 Dec; 140():105070. PubMed ID: 31518679
[TBL] [Abstract][Full Text] [Related]
18. Mesoporous Silica Nanoparticles as Carriers for Biomolecules in Cancer Therapy.
Küçüktürkmen B; Rosenholm JM
Adv Exp Med Biol; 2021; 1295():99-120. PubMed ID: 33543457
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution.
Baeza A; Manzano M; Colilla M; Vallet-Regí M
Biomater Sci; 2016 May; 4(5):803-13. PubMed ID: 26902682
[TBL] [Abstract][Full Text] [Related]
20. [Co-delivery of paclitaxel and cyclosporine by a novel liposome-silica hybrid nano-carrier for anti-tumor therapy via oral route].
Deng L; Su TT; Huang XL; Wang YH; Li C
Yao Xue Xue Bao; 2014 Jan; 49(1):106-14. PubMed ID: 24783515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
